Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 159

Sort by

Sort Order Select

Journal Articles

Biomarkers of Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - Results of the Europe Trial By the Emsco Network

Blood (2019) 134 (Supplement_1): 2998.

https://doi.org/10.1182/blood-2019-129047

Published: 2019

Journal Articles

Circulating Small Noncoding RNAs As Novel Semi-Invasive Markers of Patient Survival in Myelodysplastic Syndromes

Michaela Dostalova Merkerova, PhD MSc, Andrea Hrustincova, Zdenek Krejcik, David Kundrat, Katarina Szikszai, PhD, Jaroslav Cermak, Jitka Vesela, Monika Hruba, Monika Belickova, PhD

Blood (2019) 134 (Supplement_1): 3004.

https://doi.org/10.1182/blood-2019-126520

Published: 2019

Journal Articles

Characterization of Pathogenic Variants Associated with Hereditary Thrombocytopenias in Families from the Czech Republic

Zuzana Vrzalova, PhD, Katerina Stano Kozubik, PhD, Lenka Radova, PhD, Jakub Trizuljak, MD, Sarka Pospisilova, Prof PhD, Michael Doubek, MD PhD

Blood (2019) 134 (Supplement_1): 2343.

https://doi.org/10.1182/blood-2019-122696

Published: 2019

Journal Articles

Deep Immunoprofiling By Flow Cytometry and NGS Reveals Distinct T Cell Profile in Pediatric Hepatitis-Associated Aplastic Anemia

Michaela Novakova, Michael Svaton, MD, Martina Sukova, MD, Veronika Kanderova, MSc, PhD, Nikos Darzentas, PhD, Lenka Kramna, MSc, PhD, Ondrej Cinek, Prof., MD PhD, Dagmar Pospisilova, Prof MD PhD, Jan Trka, Prof., MD PhD, Ondrej Hrusak, MD PhD, Jan Stary, Prof., MD PhD, Ester Mejstrikova, MD PhD, Eva Fronkova, MD PhD

Blood (2019) 134 (Supplement_1): 2508.

https://doi.org/10.1182/blood-2019-127986

Published: 2019

Journal Articles

Impact of a Risk-Adapted Treatment Approach in Pediatric AML: A Report of the AML-BFM Registry 2012

Mareike Rasche, MD, Emma Steidel, Denise Kondryn, Nils Von Neuhoff, PhD, Lucie Sramkova, MD, Ursula Creutzig, MD, Michael Dworzak, MD, Dirk Reinhardt, MD

Blood (2019) 134 (Supplement_1): 293.

https://doi.org/10.1182/blood-2019-130969

Published: 2019

Journal Articles

Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia

David J. Kuter, Ralph V. Boccia, MD, Eun-Ju Lee, MD, Merlin Efraim, MD, Nikolay Tzvetkov, MD, Jiri Mayer, MD, Marek Trněný, MD, Milan Kostal, MD, Roman Hajek, MD, Vickie McDonald, MD, Olga Bandman, MD, Regan Burns, Ann Neale, Dolca Thomas, MD, Nichola Cooper, MD MRCP

Blood (2019) 134 (Supplement_1): 87.

https://doi.org/10.1182/blood-2019-122336

Published: 2019

Journal Articles

Arsenic Trioxide Upregulates Cereblon mRNA Expression and Potentiates Sensitivity of SKM-1 and MDS-L Cells to Lenalidomide

Radka Bokorová, Ota Fuchs, PhD, Denisa Myslivcova, PhD, Jaroslav Cermak

Blood (2019) 134 (Supplement_1): 5397.

https://doi.org/10.1182/blood-2019-126443

Published: 2019

Journal Articles

Nilotinib Vs Nilotinib Plus Pegylated Interferon α (Peg-IFN) Induction and Nilotinib or Peg-IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1 Positive Chronic Myeloid Leukemia Patients in Chronic Phase (TIGER Study): The Addition of Peg-IFN Is Associated with Higher Rates of Deep Molecular Response

Blood (2019) 134 (Supplement_1): 495.

https://doi.org/10.1182/blood-2019-130043

Published: 2019

Journal Articles

Alteration of Serum Malondialdehyde Level As Biomarker of Oxidative Stress during Acute Myeloid Leukemia Treatment

Alzbeta Hlavackova, PhD, Jan Vydra, MD, Leona Chrastinova, PhD, Roman Kotlin, PhD, Jana Stikarova, PhD, Jiri Suttnar, PhD, Jan E. Dyr, Prof.

Blood (2019) 134 (Supplement_1): 5181.

https://doi.org/10.1182/blood-2019-122303

Published: 2019

Journal Articles

The Role of Demographic and Social Factors on Decision Making in Patients with Relapsed and Refractory Multiple Myeloma Treated By Ixazomib, Lenalidomide and Dexamethasone

Jiri Minarik, MD PhD, Alexandra Jungova, Jan Straub, MD, Evzen Gregora, MD, Jana Bryknarova, Blanka Nemcova, Roman Hajek, MD

Blood (2019) 134 (Supplement_1): 5832.

https://doi.org/10.1182/blood-2019-130961

Published: 2019

Journal Articles

RUNX1 Mutation Accompanied with Dysregulated Cellular Senescence in Lower-Risk Myelodysplastic Syndrome Patients Is Associated with Disease Progression

Monika Hruba, Jitka Vesela, Hana Votavova, PhD, Michaela Dostalova Merkerova, PhD MSc, David Kundrat, Katarina Szikszai, PhD, Marie Lauermanova, MD, Zuzana Zemanova, PhD, Anna Jonasova, MD PhD, Jaroslav Cermak, MD PhD, Monika Belickova, PhD

Blood (2019) 134 (Supplement_1): 4230.

https://doi.org/10.1182/blood-2019-131150

Published: 2019

Journal Articles

CD Maps - Dynamic Profiling of CD1 to CD100 Surface Expression on Human Leukocyte and Lymphocyte Subsets

Karel Fišer, PhD, Tomas Kalina, MD PhD, Martin Perez-Andres, Daniela Kužílková, PhD, Pablo Engel, Marta Cuenca, PhD, Elena Blanco Álvarez, Sophinus J.W. Bartol, Menno C. van Zelm

Blood (2019) 134 (Supplement_1): 4878.

https://doi.org/10.1182/blood-2019-128123

Published: 2019

Journal Articles

Hydroxyurea Pharmacokinetic Profiles in Children Treated for Extreme Thrombocytosis after Total Pancreatectomy with Islet Cell Autotransplant Demonstrate Poor Absorption

Alexander A Boucher, MD, Min Dong, PhD, Anu Marahatta, PhD, Adriane Hausfeld, Thad A. Howard, MS, Jaimie D Nathan, MD, Alexander A. Vinks, PharmD, PhD FCP, Patrick T. McGann, MD, Russell E. Ware, MD PhD, Lori Luchtman-Jones, MD

Blood (2019) 134 (Supplement_1): 4893.

https://doi.org/10.1182/blood-2019-127378

Published: 2019

Journal Articles

Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial

Blood (2018) 132 (Supplement 1): 301.

https://doi.org/10.1182/blood-2018-99-112079

Published: 2018

Journal Articles

Whole Exome Sequencing of Residual Disease in Multiple Myeloma: Searching for Novel Therapeutic Targets

Martina Zátopková, MSc, Tereza Sevcikova, Zuzana Kufova, Katerina Growkova, Jana Filipova, Tomas Jelinek, Lucie Říhová, Renata Bezděková, MSc., Fedor Kryukov, Jana Smejkalová, Jiri Minarik, MD PhD, Vladimir Maisnar, MD, Martin Mistrik, MD PhD, Ludek Pour, MD, Alexandra Jungova, Michal Šimíček, Giovanni Stracquadanio, Roman Hajek

Blood (2018) 132 (Supplement 1): 3175.

https://doi.org/10.1182/blood-2018-99-112611

Published: 2018

Journal Articles

Switching Towards Monocytic Lineage and Discordancy between Flow Cytometric and PCR Minimal Residual Disease Results Is a Hallmark Feature of DUX4 Rearranged B-Cell Precursor Acute Lymphoblastic Leukemia

Michaela Novakova, Barbora Vakrmanova, MD, Lucie Slamova, Alena Musilova, Monika Brüggemann, Matthias Ritgen, MD, Eva Fronkova, MD PhD, Tomas Kalina, MD PhD, Jan Trka, MD PhD, Jan Stary, MD PhD, Martina Vaskova, Lucie Winkowska, Marketa Zaliova, Karel Fišer, PhD, Ondrej Hrusak, Ester Mejstrikova, MD PhD

Blood (2018) 132 (Supplement 1): 2825.

https://doi.org/10.1182/blood-2018-99-116575

Published: 2018

Journal Articles

Indirect Comparison Using Individual Patient Level Data Comparing Efficacy and Safety of a Daratumumab Monotherapy Vs. EU Approved Comparator Therapies in Patients with Multiple Myeloma

Irina Demmer, Susanne Huschens, Dietrich Potthoff, Jörg Tomeczkowski, Christian Englisch, Pushpike Thilakarathne, Joris Diels, Shaji K. Kumar, MD, Brian GM Durie, MD, Lewin Eisele

Blood (2018) 132 (Supplement 1): 3541.

https://doi.org/10.1182/blood-2018-99-116884

Published: 2018

Journal Articles

Disulfiram May Contribute to Apoptosis of Myeloma Cells By Reactivating of Cell Cycle Regulating Gene CDKN2A

Denisa Hrckova Drozdkova, Jan Gursky, PhD, Petra Luzna, Sabina Sevcikova, PhD, Jiri Minarik, MD PhD, Katerina Smesny Trtkova, PhD

Blood (2018) 132 (Supplement 1): 5125.

https://doi.org/10.1182/blood-2018-99-114743

Published: 2018

Journal Articles

Molecular and Clinical Aspects of Aα Dysfibrinogenemia in 25 Patients from the Czech Republic

Eliska Ceznerova, MSc, Jana Stikarova, PhD, Pavla Roselova, MSc, Jirina Kaufmanova, MSc, Jiri Suttnar, PhD, Jan Louzil, MD, Roman Kotlin, PhD, Peter Salaj, MD, Jan E. Dyr, prof. PhDMSc. DSc.

Blood (2018) 132 (Supplement 1): 5046.

https://doi.org/10.1182/blood-2018-99-118254

Published: 2018

Journal Articles

Ixazomib Plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (MM) Patients (Pts) - Effectiveness in Routine Clinical Practice Is Similar to the Efficacy in the Phase 3 Tourmaline-MM1 Trial: A Pooled Analysis from the Insight MM Observational Study and the Czech Registry of Monoclonal Gammopathies (RMG)

Blood (2018) 132 (Supplement 1): 1971.

https://doi.org/10.1182/blood-2018-99-113441

Published: 2018

NARROW

Biomarkers of Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - Results of the Europe Trial By the Emsco Network

Circulating Small Noncoding RNAs As Novel Semi-Invasive Markers of Patient Survival in Myelodysplastic Syndromes

Characterization of Pathogenic Variants Associated with Hereditary Thrombocytopenias in Families from the Czech Republic

Deep Immunoprofiling By Flow Cytometry and NGS Reveals Distinct T Cell Profile in Pediatric Hepatitis-Associated Aplastic Anemia

Impact of a Risk-Adapted Treatment Approach in Pediatric AML: A Report of the AML-BFM Registry 2012

Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia

Arsenic Trioxide Upregulates Cereblon mRNA Expression and Potentiates Sensitivity of SKM-1 and MDS-L Cells to Lenalidomide

Alteration of Serum Malondialdehyde Level As Biomarker of Oxidative Stress during Acute Myeloid Leukemia Treatment

The Role of Demographic and Social Factors on Decision Making in Patients with Relapsed and Refractory Multiple Myeloma Treated By Ixazomib, Lenalidomide and Dexamethasone

RUNX1 Mutation Accompanied with Dysregulated Cellular Senescence in Lower-Risk Myelodysplastic Syndrome Patients Is Associated with Disease Progression

CD Maps - Dynamic Profiling of CD1 to CD100 Surface Expression on Human Leukocyte and Lymphocyte Subsets

Hydroxyurea Pharmacokinetic Profiles in Children Treated for Extreme Thrombocytosis after Total Pancreatectomy with Islet Cell Autotransplant Demonstrate Poor Absorption

Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial

Whole Exome Sequencing of Residual Disease in Multiple Myeloma: Searching for Novel Therapeutic Targets

Switching Towards Monocytic Lineage and Discordancy between Flow Cytometric and PCR Minimal Residual Disease Results Is a Hallmark Feature of DUX4 Rearranged B-Cell Precursor Acute Lymphoblastic Leukemia

Indirect Comparison Using Individual Patient Level Data Comparing Efficacy and Safety of a Daratumumab Monotherapy Vs. EU Approved Comparator Therapies in Patients with Multiple Myeloma

Disulfiram May Contribute to Apoptosis of Myeloma Cells By Reactivating of Cell Cycle Regulating Gene CDKN2A

Molecular and Clinical Aspects of Aα Dysfibrinogenemia in 25 Patients from the Czech Republic

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only